Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pempidine SCHEMBL4798468 | 0.69 | TSHR (0.58) | TSHRNFKB1CYP2C19 | |
| Pempidine SCHEMBL217663 | 0.69 | TSHR (0.58) | TSHRNFKB1CYP2C19 | |
| SCHEMBL11453005 | 0.69 | TSHR (0.36) | TSHRNFKB1CYP2C19 | |
| SCHEMBL10812173 | 0.67 | TSHR (0.31) | TSHRNFKB1CYP2C19 | |
| SCHEMBL20504145 | 0.67 | TSHR (0.35) | TSHRNFKB1CYP2C19 | |
| SCHEMBL772228 | 0.67 | TSHR (0.35) | TSHRNFKB1CYP2C19 | |
| SCHEMBL18798641 | 0.67 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL5346 | 0.67 | TSHR (0.39) | TSHRNFKB1CYP2C19 | |
| SCHEMBL5441085 | 0.67 | TSHR (0.34) | TSHRNFKB1CYP2C19 | |
| SCHEMBL703625 | 0.67 | TSHR (0.39) | TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | claimed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | claimed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | claimed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | claimed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | claimed |
| US-9162972-B2 | Method for production of hydroxycarboxylic acid amide compounds and novel arylboronic acid compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2015-10-20 | — | — | US | disclosed |
| US-20150011766-A1 | METHOD FOR PRODUCTION OF HYDROXYCARBOXYLIC ACID AMIDE COMPOUNDS AND NOVEL ARYLBORONIC ACID COMPOUND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-2816026-A1 | PRODUCTION METHOD FOR HYDROXY-CARBOXYLIC ACID AMIDE COMPOUND, AND NOVEL ARYLBORONIC ACID COMPOUND | National University Corporation Nagoya University (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8735582-B2 | Method for producing carboxylic anhydride and arylboronic acid compound | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | TSHR 2969/4885NFKB1 2136/4885CYP2C19 4794/4885 |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | TSHR 2356/4885NFKB1 1500/4885CYP2C19 1334/4885 |
| US-20150011766-A1 | METHOD FOR PRODUCTION OF HYDROXYCARBOXYLIC ACID AMIDE COMPOUNDS AND NOVEL ARYLBORONIC ACID COMPOUND | HCAR2, HCAR1, NCOR2 | TSHR 580/4885NFKB1 538/4885CYP2C19 205/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | TSHR 2356/4885NFKB1 1500/4885CYP2C19 1334/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | TSHR 2356/4885NFKB1 1500/4885CYP2C19 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.